Investigators have identified and validated the peak early-phase enhancement ratio (PEER) radiographic measurement for accurately differentiating CD117+ renal oncocytoma from CD117+ chromophobe renal cell carcinoma (RCC). Retrospective analysis revealed the most reliable variable for tumour differentiation was the tumor:cortex PEER using multiphase CT. In prospective validation, PEER had 100% accuracy in differentiating tumours.